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Abstract
 
A natural serum autoantibody specific for the Thy-1 glycoprotein (anti–Thy-1 autoantibody
[ATA]) is produced by B-1 cells that are positively selected by self-antigen. Here, using
ATA
 
   
 
transgenic mice we show that cells with this B cell receptor are negatively selected
during bone marrow (BM) development. In a Thy-1 null environment, BM ATA B cells
progress to a normal follicular stage in spleen. However, in a self-antigen–positive environ-
ment, development is arrested at an immature stage in the spleen, concomitant with induction
of CD5. Such cells are tolerant and short-lived, different from B-1. Nonetheless, ATA-positive
selection was evident by self-antigen–dependent high serum ATA production, comprising
 
 
 
90% of serum immunoglobulin M in ATA
 
   
 
mice. Splenectomy did not eliminate ATA
production and transfer of tolerant splenic B cells did not induce it. These findings demonstrate
that B-1 positive selection, resulting in the production of natural serum ATA, arises indepen-
dently from the major pathway of BM B cell development and selection.
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Introduction
 
Developing B cells pass through several key checkpoints
that they must traverse to survive and mature. Premature B
cell receptor (BCR)
 
* 
 
signaling due to autoreactivity leads
to negative consequences, termed “negative selection” or
“tolerance” (1–3). Thus, B cells with potentially hazardous
autoreactive specificities are prevented from maturing, re-
sulting in a lack of pathogenic serum autoantibody (4–6).
However, a type of autoreactive B cell present in normal
healthy individuals has been long-recognized as the source
of natural autoreactive antibody in serum (7–10). A signifi-
cant proportion of this autoantibody appears to derive from
a specific B cell compartment, B-1. These cells reside pref-
erentially in the peritoneal cavity (PerC) and intestinal lam-
ina propria, in contrast to the majority of B cells that popu-
late the conventional lymphoid organs. B-1 B cells often
express CD5 and are enriched for autoreactive specificities,
particularly to carbohydrate epitopes on self-glycolipids or
glycoproteins (11–14).
Anti–Thy-1 autoantibody (ATA) is one of the classic
natural serum antithymocyte autoantibodies (8, 15).
The ATA encoded by germline V
 
H
 
3609-D
 
Q52/FL8.2
 
-J
 
H
 
2/
V
 
 
 
21C-J
 
 
 
2 Ig heavy and light chain genes derives from the
SM6C10 hybridoma made from CD5
 
  
 
B-1 B cells (16,
17). This ATA recognizes a glycosyl determinant restricted
to mouse Thy-1 (CD90) expressed on the majority of thy-
mocytes and a fraction of peripheral T cells, as a species-,
cell type–, and development-specific self-antigen (18). The
exact glycosyl antigen form is unclear at present, however,
thymocytes/T cells are considered as the major source of
physiologic self–Thy-1 antigen. Importantly, we previously
showed that in V
 
H
 
3609
 
  
 
transgenic (Tg) mice, the normal
accumulation of CD5
 
  
 
ATA B cells in the PerC and the
production of serum ATA did not occur in the absence of
Thy-1, providing a model for B-1 B cell positive selection
in association with the production of natural serum autoan-
tibody (16, 17).
The precise details of the development of these ATA B-1
cells remains to be established. In particular, it was unclear
whether they arose during the course of normal bone
marrow (BM) B cell development. The generation of B-1
cells initially occurs in the fetal liver (12), diminishing as
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, thymocyte plasma
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primary development shifts to the BM after birth. B-1 cell
generation gradually declines during the first several weeks
of postnatal life, whereas there is increasing production of
follicular B cells, the major population of B cells found in
typical lymphoid sites (19, 20). The reason for the decline
in B-1 cell generation is a long-standing puzzle. One mech-
anism is a defect in an early pre–B cell checkpoint, specifi-
cally critical in BM B cell development, as seen with V
 
H
 
11
rearranged heavy chain due to failure of 
 
  
 
heavy chain
to assemble with surrogate light chain (21). However,
V
 
H
 
3609
 
  
 
heavy chain is capable of assembling with surro-
gate light chain, generating a pre-BCR (unpublished data),
so V
 
H
 
3609
 
  
 
rearranged B cells should complete normal
early BM B cell development, with the V
 
H
 
3609
 
  
 
heavy
chain becoming associated with diverse Ig light chains.
Thus, BM would be predicted to continually give rise to
the ATA specificity as a component of the normal reper-
toire of newly generated B cells available for subsequent se-
lection checkpoints. This study assessed the fate of such
newly generated ATA B cells from the BM to spleen, the
site of final peripheral maturation, to determine whether
positive selection into the B-1 compartment occurs, con-
tributing to natural serum autoantibody production.
 
Materials and Methods
 
Mice.
 
C.B17, BALB/c, C.B17 SCID, Thy-1
 
 
 
/
 
 
 
.CB17, and
J
 
H
 
 
 
/
 
 
 
.CB17 were bred and maintained in our laboratory animal
facility. The ATA
 
  
 
Tg mouse line (ATA1) expressing a V
 
H
 
3609-
 
 
 
a 
 
Tg on a C.B17 background was previously described (17). To
establish ATA
 
   
 
(V
 
H
 
3609
 
 
 
/V
 
 
 
21C) Tg mouse lines, a V
 
 
 
21C
rearranged kappa light chain gene was cloned from the SM6C10
hybridoma (16). DNA extracted from the SM6C10 hybridoma
was cut with MunI. The rearranged V
 
 
 
21C was identified on a
Southern blot by hybridizing with a pEC
 
  
 
probe and also with a
V
 
 
 
21C fragment made by PCR amplification, and then DNA
was size-fractionated and a lambda phage library was made with
EcoRI precut Zap Express (Stratagene). The phage colonies were
screened with the pEC
 
  
 
probe, rescreened with V
 
 
 
21C, and
then the phage containing the rearranged kappa gene was con-
verted into plasmid (pBK-CMV vector). The V
 
 
 
21C gene insert
was freed of plasmid DNA using NotI and SalI and then coin-
jected with purified V
 
H
 
3609-
 
  
 
insert into (C3H 
 
  
 
C57BL/6)F
 
1
 
eggs. Among the first offspring, PCR tail DNA showed 7/49
3609
 
 
 
 
 
/V
 
 
 
21C
 
 
 
, all cointegrated. Six Tg
 
  
 
 lines were then
bred to C.B17 mice, selecting H-2
 
d/d 
 
at the second generation
with continued crossing to C.B17 for several (
 
 
 
4) generations.
One founder line, 3369, was used in this study as a representative
non-BCR editing ATA
 
   
 
Tg line. ATA Tg
 
  
 
mice with Thy-
1
 
 
 
/
 
  
 
and Thy-1
 
 
 
/
 
  
 
backgrounds were generated by backcrossing
with Thy-1
 
 
 
/
 
 
 
.CB17 as previously described. Both females and
males were used at 6–12 wk for most studies. All mice were
maintained under specific pathogen-free conditions. Studies were
performed according to institutional guidelines for animal use
and care.
 
Anti-ATA Idiotype Antibody.
 
SM6C10 IgM antibody was pu-
rified from ascites followed by absorption with protein A–Seph-
arose 4B beads (Sigma-Aldrich) to eliminate copurified IgG2b.
Sprague-Dawley rats purchased from Taconic were hyperimmu-
nized subcutaneously weekly four times, initially with 200 
 
 
 
g
SM6C10 in CFA, next with 200 
 
 
 
g in IFA once, and then with
100 
 
 
 
g in IFA twice. 1 mo after the last immunization, a rat was
boosted with 50 
 
 
 
g SM6C10 (soluble, no adjuvant) and spleen
cells were fused with SP2/0 3 d later. Antiidiotype specificity was
screened by comparing reactivity to SM6C10 and control non-
ATA IgM (SM3G11; reference 16) by ELISA assay, by SM6C10
thymocyte staining inhibition activity using FACS
 
®
 
, and by com-
paring staining of ATA
 
   
 
Tg, ATA
 
  
 
Tg, and non-Tg mouse B
cells. Fine specificity was then examined by ELISA using various
hybridoma IgMs. The selected hybridoma, P9-19A4, is a rat
IgG2a.
 
Antibody Reagents, Flow Cytometry Analysis, and Cell Sorting.
 
The following hybridoma antibodies were used in this study:
IgM (331.12), IgM
 
a 
 
(RS-3.1), IgM
 
b 
 
(AF6-78), IgD
 
a 
 
(AMS-15),
CD45R/B220 (RA3-6B2), CD5 (53-7.3), CD21 (7G6), CD23
(B3B4), CD24/HSA (30F1), CD62L/
 
l
 
-selectin (MEL-14),
AA4.1 (22), and ATA idiotype (P9-19A4). Most monoclonal an-
tibody reagents used for four to six color flow cytometry analysis
were prepared in our laboratory by purifying antibodies and cou-
pling to either fluorescein (FL), PE, allophycocyanin, or biotin
(revealed by Texas Red–conjugated avidin). Cy7-PE–coupled
antibody was made by first precoupling Cy7 dye (Amersham
Biosciences) to R-PE (QuantaPhy). Cascade blue labeling re-
agent was purchased from Molecular Probes. FL–anti-CD21 was
purchased from BD Biosciences. A modified FACStarPlus™ dye
laser dual laser flow cytometer (BD Biosciences) was used in most
four color analyses and cell sorting. A dye laser/Argon ion laser
FACSVantage™ SE (BD Biosciences) with an additional Kryp-
ton laser (INNOVA 302C; Coherent) was used for six color
analysis and the calcium mobilization experiment.
 
Thymocyte Plasma Membrane (Thy
 
M
 
) Isolation.
 
A plasma mem-
brane fraction was prepared using a standard procedure. In brief,
thymocytes from 10 mice were suspended in homogenizing
buffer (25 mM Tris, 1 mM MgCl
 
2
 
, 30 mM NaCl) at 5 
 
  
 
10
 
8
 
/ml
and homogenized. After removing debris, the supernatant was
applied to 41% sucrose in homogenizing buffer and centrifuged at
92,000 
 
g 
 
for 1 h at 4
 
 
 
C. The interphase was harvested and washed
twice at 64,000 
 
g
 
 for 30 min, and then resuspended in 1 ml sterile
PBS and stored at 
 
 
 
70
 
 
 
C. The yield was 2–3 mg protein (OD
 
280
 
)
from 2 
 
  
 
10
 
9 
 
thymocytes.
 
Cell Culture.
 
Various cell sorter purified spleen B cell
(B220
 
 
 
) fractions were cultured in U-bottomed 96-well culture
plates (3799; Costar) at 5 
 
  
 
10
 
4 
 
cells in 150 
 
 
 
l/well of culture
medium (RPMI 1641, 10% FCS, 50
 
 
 
M 2-ME) with or without
stimulation. 2–3 d after culture, cells were harvested, propidium
iodide was added, and cells were analyzed by FACS
 
®
 
, determin-
ing total cell number, dead cell number, and change in cell size.
 
Bromodeoxyuridine (BrdU) Labeling and Analysis.
 
The BrdU
labeling and analysis together with simultaneous cell surface stain-
ing were performed as described elsewhere (23, 24) with a minor
modification to facilitate the cell staining procedure in a 96-well
flexible plate. Mice were injected with BrdU (Sigma-Aldrich) 0.6
mg /0.2 ml PBS intraperitoneally twice a day for 3 d, and killed
12 h after the last injection for the initial BrdU-labeled cell analy-
sis. Cell surface staining (using PE, allophycocyanin, and biotin/
Texas Red–coupled reagents) was performed on ice in a plate
(10
 
6 
 
cells/well for each analysis) and placed at room temperature.
After washing twice with PBS, cells were fixed and permeabilized
by using commercial solutions at room temperature (30 
 
 
 
l/well
for 15 min for each step, Fix and Perm; Caltag Laboratories),
DNase I treated (5 mg/ml in DNase solution, pH 5.0, 100 
 
 
 
l/
well, for 30 min; Sigma-Aldrich), and then incubated with FL–
anti-BrdU (BD Biosciences) in 3% FCS containing staining me-
dium (25 
 
 
 
l/well for 30 min). Between each treatment step,T
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cells were washed twice with PBS (100–150 
 
 
 
l/well) by multipi-
pette resuspension followed by centrifugation. Anti-BrdU–
stained cells were washed with staining medium and analyzed on
a FACSVantage™ flow cytometer. Similarly stained/treated cells
without the last anti-BrdU staining step and the cells from BrdU-
uninjected mice were used as controls to determine the FL back-
ground of respective B cell populations.
 
Calcium Mobilization Assay.
 
The protocol used was described
elsewhere (25) with some modifications. Preparation of spleen
cells, erythrocyte lysis, and surface staining were all performed at
room temperature with deficient RPMI 1640 medium (Irvine
Scientific) containing 10 mM Hepes plus 3% FCS (“Indo loading
buffer”). Surface stained cells were washed once and resuspended
at 5 
 
  
 
10
 
6
 
/ml and loaded with 8 
 
 
 
M Indo-1 a.m. (Sigma-
Aldrich) together with Pluronic F-127 (0.01% w/v final; Molec-
ular Probes) for 45 min at 37
 
 
 
C. After washing twice, each 2 
 
  
 
10
 
6
 
cell sample was resuspended in 0.5 ml per tube and prewarmed to
37
 
 
 
C for 10 min just before analysis. Data were collected for 30 s
to establish the baseline violet/blue (405:485 nm) ratio, and then
stimulated by the addition of 30 
 
 
 
g/ml Thy
 
M
 
. Data were col-
lected for a total of 5 min. Rat anti–IgM (B7-6) and A23187 ion-
ophore (Sigma-Aldrich) were used to reveal peak BCR signaling
and maximal calcium mobilization. Data were analyzed using
FlowJo
 
® 
 
software (Tree Star Software).
 
Serum ATA Titer and ELISA Assay.
 
ATA activity in the se-
rum was tested by thymocyte staining analysis using 1:10 diluted
serum in combination with FL–anti-IgM as a second step anti-
body as previously described (17). To quantitate IgM/
 
  
 
antibody
for total IgM, Id
 
  
 
IgM, IgM
 
a
 
, and IgM
 
b 
 
in an ELISA assay,
anti-IgM (331.12)/biotin-anti–mouse 
 
  
 
(187.1), 19A4/biotin-
anti–mouse 
 
  
 
(or anti-IgM), anti-IgM/biotin–anti-IgM
 
a
 
, and anti-
IgM/biotin–anti-IgM
 
b 
 
were used as plate coating and second step
reagent combinations, respectively, followed by incubation with
alkaline phosphatase–conjugated avidin as the third step reagent.
TEPC183 (IgM
 
a
 
 
 
, ATA id ), SM6C10 (IgMb , ATA id ), and
H30-2C3 (IgMa , ATA id ; reference 17) antibodies were used
as standards.
Adoptive Cell Transfer. 1 2   106 cell sorter purified B cell
(B220 ) fractions were injected into the tail vein of recipient mice
that had been lightly irradiated (300 rad) 1 d before use. Serum was
harvested by orbital bleeding at designated times after injection.
Splenectomy (splx). Adult splx was performed by a standard
protocol. In brief, 2-mo-old mice were anesthetized and a small
incision was made to expose the spleen. The spleen was removed
using a portable cautery unit to burn and seal connecting blood
vessels. The body wall was closed by vicryl suture and the skin
was closed with wound clips. Manipulated mice were kept in a
laminar flow–equipped cage rack but without antibiotics. All
mice maintained a healthy appearance.
Results
Self-antigen–dependent CD5 Induction at the Immature
AA4.1  Stage. As previously described (17), the positive
selection of ATA B cells is evident in the analysis of PerC
cells of VH3609  Tg mice (ATA  Tg; Fig. 1). ATA B
cells, expressing the VH3609  transgene (Tg ) in combi-
nation with endogenous V 21C-J 2, comprised 30–80% of
the Tg   endogenous   (Endo  )  B cells in the PerC of
Thy-1  ATA  Tg mice, as detected by the anti-ATA idio-
type antibody, 19A4, but such cells were infrequent or ab-
sent in Thy-1  mice (Fig. 1 A, PerC). This self-antigen–
dependent increase in ATA B cells was accompanied by in-
creased natural serum ATA (17). In the same ATA  Tg
mouse, a few ATA B cells were detectable as a cluster of
“on-diagonal” cells in the BM and spleen by flow cytome-
try analysis, exhibiting the highest binding of 19A4 antiid-
iotype antibody, relative to IgM (Tg ) level as indicated
(Fig. 1 A).  80% of the 19A4hi-stained cells in this diago-
nal region had rearrangement of V 21C-J 2, as determined
by single cell cDNA kappa chain sequencing. The cells that
exhibited a lower 19A4-Id/Tg   ratio lacked this rear-
rangement but were enriched for usage of other V 21 gene
members or showed V 21C rearranged to different J  seg-
ments (not depicted).
ATA B cells comprised  0.4% of newly formed Tg   B
cells in the BM, regardless of Thy-1  or Thy-1  back-
ground, confirming that ATA B cells are generated in the
BM with the expected frequency in ATA  Tg mice. The
ATA B cell frequency was only marginally higher in the
spleen of Thy-1  mice compared with Thy-1  (6 vs. 2% of
total Tg   B cells) in contrast to the PerC. However, al-
though the newly formed ATA B cells in the BM did not
express CD5, half of the ATA B cells in the spleen showed
self-antigen–dependent CD5 expression at a level compa-
rable to PerC ATA B cells (Fig. 1 B). No other Tg  
(Endo  ) cells, including low 19A4-Id–stained cells in the
spleen, showed CD5 induction. Thus, Thy-1 antigen ex-
posure and CD5 induction occur during ATA B cell devel-
opment from BM. Distinctively, however, the majority of
these CD5  ATA B cells in the spleen were CD24/HSAhi
AA4.1  CD21  and showed lower expression of lymph
node homing receptor CD62L, a phenotype associated
with immature B cells (24, 26, 27). In contrast, the CD5 
ATA B cells in the PerC were CD24/HSAmed AA4.1 
CD21lo CD62L , a phenotype typical of long-lived B-1
cells in normal mice (Fig. 1 C). The predominance of im-
mature CD5  ATA B cells in the spleen continued even in
aged mice, suggesting that negative selection might be oc-
curring in the spleen.
Maturational Arrest of ATA B Cells. To explore the
possibility of negative selection, VH3609 /V 21C   Tg
mice (ATA   Tg) were made, in which all newly formed
BM B cells expressed the ATA specificity. All six Tg
founder lines showed exclusive expression of the ATA
transgene by newly generated B cells in BM. In contrast, B
cell profiles in the spleen showed some differences, falling
into two patterns depending on founder line (Fig. 2 A): ei-
ther exclusive maintenance of the ATA BCR but with de-
creased circulating B cells (represented by 3369 line, as
will be detailed in this study), or else a predominance of
“off-diagonal” B cells with a lower 19A4-Id/Tg  ratio,
due to a high incidence of BCR editing by expression of
endogenous light chains (3345 line). Regardless, common
to all lines, ATA B cells in the spleen retained a predomi-
nantly CD24/HSAhi and AA4.1  immature phenotype, a
sign of arrest of maturation in the normal Thy-1  environ-
ment (Fig. 2 A). There was no apparent abnormality in the
thymus or peripheral T cell compartment in any of the
lines.T
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These AA4.1  ATA B cells in ATA   Tg mice could
mature if self-antigen was absent. Fig. 2 B shows analysis of
Thy-1–positive and –negative littermates of the non-
BCR–editing ATA    Tg line 3369. Newly generated
B220   B cells in BM (CD24/HSAhi  CD21   CD23 
AA4.1hi; reference 27) were CD5  and present at similar
frequencies, regardless of Thy-1 exposure (Fig. 2 B, BM).
In mice with a Thy-1  background, the majority of ATA
B cells became CD5  in the spleen and most remained at
the CD24/HSAhi  CD21   AA4.1   immature stage with
variable expression of CD23. In contrast, in Thy-1 / 
mice, ATA B cells remained CD5  and the majority pro-
gressed to a mature follicular B cell phenotype (CD24/
HSAlow CD21  AA4.1  CD23 ; Fig. 2 B, Spleen). Al-
Figure 1. Distinction between
spleen and PerC CD5  ATA B
cells. Cell surface staining analy-
sis of ATA  Tg Thy-1 /  versus
Thy-1    littermates. (A) Detec-
tion of Tg   Id  ATA B cells by anti-
idiotype 19A4 antibody. Endogenous   
(IgMb ) cells were gated out in the figure
(IgMb  cells;  1% in BM, 2% in spleen, and
50% in PerC) by staining with anti-IgMb
along with the other staining reagents. BM
and spleen cell data are presented as 10%
probability contour plots with final 10%
outliers shown as dots. PerC data are shown
as 5% probability contour plots. Arrows
point to the 19A4hi-stained ATA B cell di-
agonal cluster. The Tg -positive region is
marked by a thin line ( 8 units of IgMa
staining). The ATA /Tg   B cell frequen-
cies of Thy-1 /   versus Thy-1 /   back-
ground mice were 6 and 2% in the spleen
and 35 and 1% in PerC, respectively. To
obtain frequency data specific for newly
generated B cells, the BM cells were stained
to detect AA4.1  CD23  Tg   newly gen-
erated B cells together with 19A4. 0.4% of
BM newly generated B cells were Id  on
both Thy-1   and Thy-1   backgrounds
(0.3–0.6% in four independent analyses). (B)
Self-antigen–dependent CD5 induction on
ATA B cells. CD5 levels of ATA B cells,
marked in A, in Thy-1 /  mice (thick line)
versus Thy-1 /  mice (thin line). No other
Tg   Endo    cells showed CD5 expression.
(C) Different surface phenotype by the
CD5-induced ATA B cells in spleen
(shaded) versus PerC (open).T
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Figure 2. Self-antigen–medi-
ated developmental arrest and
rapid turnover of CD5-induced
ATA B cells in spleen. (A) Com-
parison between ATA    Tg
mice founder lines. Shaded histo-
grams show the immature surface
phenotype of spleen ATA B cells
(diagonal region) in comparison
to the more mature phenotype
(solid line histograms) by the
BCR-edited cells in the 3345
line (dotted box). (B) Develop-
mental arrest at the AA4.1  cell
stage. Cell surface staining analy-
sis of 3369 ATA   Tg Thy-1 / 
versus Thy-1    littermates. The
region of B220  B cells used for
CD24/CD21, CD23/AA4.1,
and CD5 analysis is shown in the
box. B220   cells in spleen of
Thy-1   versus Thy-1   back-
ground were 35 and 40%, re-
spectively. (C) Rapid turnover
by self-antigen–exposed AA4.1 
ATA B cells. On the left, BrdU 
frequency in spleen B cells
(B220 ) after 3 d of BrdU injec-
tions (0.5 d after the last BrdU
injection) is shown. Data from
three mice per group is shown.
BM B220   cell BrdU labeling
was  95% in all mice. On the
right, disappearance of BrdU  la-
bel from AA4.1  cells after cessa-
tion of BrdU injection is shown.
Data from total B220  cells or
AA4.1 -gated B cell fraction
from Thy-1  3369 ATA    Tg
mouse spleen is shown. The BM
B220  cell BrdU  cell frequency
decreased to 5% 4 d after cessa-
tion. Representative data are
shown. (D) Lower B cell fre-
quency in PBL resulting from
self-antigen exposure. Analysis of
PBL of 3369 ATA    Tg   
C.B17.Thy-1 /  backcrossed lit-
termates. Data from three litters
at 5–6 wk of age.T
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though spleen B cell numbers were similar in Thy-1  and
Thy-1  mice, ATA B cells in Thy-1  mice showed a rapid
turnover rate in contrast to those in Thy-1  or non-Tg
mice (Fig. 2 C). More than half of AA4.1  B cells in Thy-
1  ATA   Tg mice in the spleen were rapidly labeled by
BrdU in 3 d and such labeled cells disappeared quickly, in-
dicating cell death and constant cell turnover. This resulted
in fewer circulating B cells in the peripheral blood in Thy-
1  ATA   Tg mice in contrast to Thy-1  background
mice (Fig. 2 D).
To test whether these self-antigen–exposed ATA B cells
could respond to antigen ex vivo, spleen cells and ATA B
cells were purified from mice and stimulated with a soluble
Thy-1–containing thymocyte plasma membrane prepara-
tion (ThyM) in vitro (Fig. 3). Although ATA B cells from
Thy-1  mice could be activated and proliferated in re-
sponse to ThyM, spleen cells from Thy-1  ATA    Tg
mice did not show any sign of activation (Fig. 3 A). This
ThyM–mediated B cell activation of Thy-1  mouse spleen
was BCR specific and could occur independent of T cells,
as shown by dose dependent, Thy-1–specific activation of
purified ATA B cells as revealed by increased cell size (Fig.
3 B). AA4.1  CD23  ATA B cells, the predominant B cell
fraction in Thy-1  mouse spleen, exhibited functional ma-
turity as shown by the longest survival in culture and high-
est ThyM-specific response. In contrast, the AA4.1  B cell
fraction, predominant in Thy-1  mice, showed the poorest
survival when Thy-1M was added to the culture (Fig. 3 C).
The effect of antigen preexposure was evident by a high
intracellular Ca2  level, already approaching that induced
by antigen stimulation of naive B cells as previously re-
ported for tolerant B cells (28). The addition of Thy-1M
only marginally mobilized Ca2  (Fig. 3 D), resulting in
eventual cell death upon further culture (Fig. 3 C). These
data confirm that AA4.1  CD5-induced ATA B cells in the
spleen were self-antigen exposed and had undergone matu-
rational arrest and tolerance with reduced lifespan as a form
of negative selection.
Lastly, we tested the possibility that a more normal di-
verse B cell repertoire during maturation might spare ATA
B cells from negative selection in contrast with the ex-
tremely skewed B cell repertoire in    Ig Tg mice. How-
ever, the generation of 2% ATA   Tg BM chimeric mice
(cotransferring ATA   Tg BM together with an excess of
non-Tg BM cells) yielded a similar predominance of
AA4.1  CD5  ATA B cells in spleen (unpublished data).
Taken together, results from studies of ATA  Tg, ATA  
Tg, and these BM chimeric mice all indicate that ATA B
Figure 3. Tolerant self-antigen–exposed ATA B cells in spleen. (A)
Lack of antigen-specific proliferation by the self-antigen–exposed spleen
ATA B cells. Staining analysis of 4-d cultured Thy-1  or Thy-1  ATA  
Tg mouse spleen cells stimulated with soluble thymocyte membrane
ThyM (thick line) or without stimulation (thin line). (B) T cell–indepen-
dent antigen-specific activation of naive mature ATA B cells. B220 
AA4.1  CD23  ATA B cells were purified from Thy-1    ATA   Tg
mouse spleen and cultured for 2 d. Activation was measured by the in-
creased cell size in mean forward scatter relative to nonstimulated cultures (taken to be 100) by FACS®. Stimulation was with ThyM ( ) or Thy-1  thy-
mocyte membrane Thy M ( ). ThyM did not stimulate B cells from non-Tg mice ( ). (C) Promotion of cell death of the self-antigen–exposed AA4.1 
B cells by ThyM. Spleen cells of 3369 Thy-1 /  or Thy-1    mice were stained with antibodies to B220, AA4.1 (AA4), and CD23, and respective B220 
cell fractions were purified and then cultured with or without stimulation (ThyM at 1  g/ml) for 2 d. Data from triplicate cultures is shown. The cell re-
covery ratio is the ratio of live cell numbers with/without ThyM stimulation. Cell size was gated on live cells after culture with (solid line) or without
ThyM (dotted line). (D) Calcium mobilization analysis. Spleen cells were prepared and stained similar to C. Data gated for the designated B cell fractions
are shown. Stimulation with ThyM (thick line) or Thy M (thin line). Indo-1 violet/blue ratio is shown as relative [Ca2 ]i.T
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cells are negatively selected in the major B cell develop-
ment pathway from BM.
AA4.1  Maturational Arrest Comparable to the IgMhi IgDlo
Stage. One perplexing aspect of our analysis was the ob-
servation that a fraction of tolerant AA4.1  ATA B cells in
the Thy-1  ATA    Tg mice showed the induction of
CD23, a phenotype commonly considered as a mature B
cell marker (29). Predominance of CD23  B cells, with co-
expression of AA4.1 and CD5, is commonly observed in
analyses of self-antigen–exposed ATA B cells in the spleens
of mice older than 2 mo. However, CD23 induction can
occur as early as the CD24/HSAhi immature IgMhi IgDlo
stage, and continues through transitional AA4.1  stages in
normal mice (24, 27). To identify the IgM/IgD phenotypic
stage in normal mice that corresponds to this ATA Tg B
cell–arrested stage, we performed six color flow cytometry
analysis. In normal mice, B cell maturation in the spleen is
characterized by quantitative and qualitative changes in the
BCR IgM/IgD ratio (30), where newly exported B cells
have not yet fully up-regulated expression of IgD. As
shown in Fig. 4, the ATA B cell phenotype associated with
maturation arrest, i.e., CD24/HSAhi CD21lo and AA4.1 
(with or without CD23 induction), corresponds to the
IgMhi IgDlow stage (a), but not to other stages. The surface
phenotype of the majority of ATA B cells in Thy-1  mice
is comparable to the IgMlow IgDhi (Fig. 4 c) mature follicu-
lar stage. Thus, negative selection of ATA B cells occurs at
the stage corresponding to IgMhi IgDlow immature cells in
normal mice before additional up-regulation of IgD and
follicular B cell generation.
Natural Serum ATA Production Independent of Tolerant B
Cell Generation. The analysis of B cell development in the
spleen presented above is entirely consistent with negative
selection predominating. In accord with this spleen cell tol-
erance, there were fewer PerC B cells in the ATA   lines.
Total B cell numbers in PerC were approximately one
third of non-Tg mice, suggesting an effect of predominant
BM B cell negative selection in the PerC, as with the de-
crease of B cells in the blood circulation. Most of these
PerC ATA B cells in ATA   Tg mice were CD11b/
Mac-1 , but showed low to undetectable surface CD5 ex-
pression compared with spleen CD5  ATA B cells (unpub-
lished data). This CD5lo/  PerC B cell feature is reminis-
cent of PerC B cells in another autoreactive B cell model
rescued from negative selection due to a decreased autoan-
tigen environment (31).
Analysis of serum ATA, however, revealed a contrast-
ing profile from that expected for negative selection. In
conventional negative selection, tolerance induction of
autoreactive B cells by exposure to self-antigen is accom-
panied by reduction of “spontaneous” autoantibody in the
serum as a result of premature cell death or induction of
anergy (4–6). In contrast, for ATA as a B-1 cell–associated
natural autoantibody, the presence of self-antigen posi-
tively influenced serum ATA levels, consistently in both
ATA  and ATA   Tg mice. All six ATA   founder
lines showed higher serum ATA titers than the ATA  Tg
lines on a self–Thy-1 antigen–positive, physiologic back-
ground (Fig. 5 A). In these ATA   Tg mice, ATA con-
stituted  90% of total serum IgM, whereas in the absence
of self-antigen this decreased to 10% in the nonediting
line 3369 (Fig. 5 B). Thus, serum ATA production was
largely self-antigen dependent, the reverse of what is nor-
mally observed in conventional B cell tolerance models of
negative selection.
PerC B-1 cells have been known to migrate and differ-
entiate into plasma cells in the intestinal lamina propria (13,
32–34). Histological analysis of the intestinal lamina propria
of ATA   Tg mice showed plasma cell infiltration at levels
significantly higher than transgene negative littermates,
whereas there was no significant increase in plasma cells in
the spleen, lymph nodes, liver, or BM (unpublished data).
This suggested accelerated plasma cell differentiation in the
intestinal mucosa resulting from expression of the ATA
specificity. Although self-antigen–exposed spleen AA4.1 
ATA B cells did not spontaneously secrete antibody in
vitro, they were readily induced to secrete antibody in re-
sponse to LPS stimulation (unpublished data). B-1 cells in
Figure 4. Arrested ATA B cell
surface phenotype, comparable to
the IgMhi IgDlo cell stage. BALB/c
spleen cell analysis by simultaneous
six color staining (IgM, IgD, CD24/
HSA, CD21, CD23, and AA4.1).
Non-naive CD21hi  HSAmed-stained
cells (9% of total IgM  cells, the
majority are IgMhi  IgDlo  AA4.1 
CD23lo/   marginal zone B cells)
were electronically excluded in this
figure presentation. The IgM/IgD
based regions gated as a, b, and c are
shown on the left.T
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normal and ATA  Tg mice are also sensitive to LPS (17,
35). Considering that intestinal microfloral bacteria could
serve as a potential LPS source in the region, the combina-
tion of self-antigen (Thy-1) exposure and subsequent LPS
stimulation after migration into the intestinal site was a po-
tential scenario for the induction of Ig secretion.
To distinguish whether natural serum ATA production
was a consequence of the vast increase of arrested ATA B
Figure 5. Self-antigen–dependent natural serum ATA production indepen-
dent from tolerant AA4.1  spleen B cell generation. (A) Serum ATA titer in-
crease in the ATA   Tg line. Thymocyte staining data with sera from 2-mo-old
mice (at 1/10 dilution). Representative data are shown. (B) Self-antigen pro-
moted natural serum ATA production in ATA   Tg mice. Summary of ELISA
assay of sera from 3369 ATA   Tg   Thy-1   .C.B-17 backcrossed littermates
(total IgM, IgMa , IgMb , and Id  IgM). Nearly all IgMa  antibody in 3369
Thy-1 /  mouse sera was ATA Id . IgMa  plus IgMb  data were comparable to
total IgM. ATA reduction in Thy-1  mice was also observed in the thymocyte
staining assay (2–15% with Thy-1    compared with Thy-1 /  3369 mice). (C)
Lack of serum ATA after adoptive transfer of spleen AA4.1  ATA B cells in con-
trast to production after the transfer of PerC ATA B cells. Thymocyte staining
with sera from recipients 3 d after injection with 3   105 PerC B220  cells into
JH
 /  mice (thick line), or 106 spleen B220  AA4.1  cells into either JH
 /  mice
(thin line) or SCID mice (dotted line). Results are representative of three inde-
pendent experiments. (D) Splenectomy (Splx)-resistant serum ATA. On the left,
thymocyte staining with sera from a 3369 mouse 1 d before (shaded) and 7 d after
splx (solid line), in comparison to non-Tg serum (dotted line) is shown. On the
right, ELISA assay data of sera before or after operation. Sham-operated ATA  
Tg ( ), splx ATA   Tg ( ), and splx non-Tg ( ) mice. Three mice per group.
(E) Disappearance of BrdU-labeled cells from PerC. Analysis after 3-d BrdU la-
beling and cessation. ATA B cells in Tg mice were identified as Id  cells.T
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cells in ATA   Tg mice or instead derived from B-1 cells
generated as a minor population, a cell transfer experiment
was performed. AA4.1  ATA B cells were purified from
Thy-1  ATA   Tg mouse spleen and transferred into B
cell–deficient JH
 /  mice, providing both normal Thy-1
self-antigen and an intestinal microfloral environment. For
comparison, total PerC B cells were harvested and also
transferred at the same time because 5–10% of PerC ATA
B cells were CD5 , potentially identifying the B-1 cells. As
shown in Fig. 5 C, although injection of PerC B cells re-
sulted in serum ATA induction shortly after transfer into
JH
    mice (within 3 d) that increased additionally by day 7,
mice receiving AA4.1  ATA B cells, even with threefold
more cells, did not show significant serum ATA (Fig. 5 C)
over a 14 d survey period. Injection of AA4.1  B cells into
SCID mice lacking both B and T cells, in an attempt to in-
crease the chance for escape from Thy-1 antigen–mediated
tolerance, also failed to reveal the induction of serum ATA
(Fig. 5 C, dotted line). These cell transfer results suggest
that although PerC B cells contain the cells responsible for
serum ATA production, maturation-arrested B cells in
spleen only rarely contribute to serum ATA.
However, there was the possibility that our cell purifica-
tion and transfer procedures might have promoted the
death of short-lived AA4.1  ATA B cells. Thus, as an alter-
native approach, we performed splx to directly estimate the
extent of spleen B cell contribution to natural serum anti-
body, taking advantage of the fact that AA4.1  cells were
the major B cell component in spleen of ATA   Tg mice.
Although splx resulted in some reduction of serum ATA in
ATA   Tg mice shortly after the operation, the presence
of splx-resistant ATA was nonetheless clear and persisted
(Fig. 5 D). Splx ATA   Tg mice showed levels higher
than the average serum ATA of ATA  Tg mice (Fig. 5, D
and A, respectively). Considering the known short half-life
of IgM (36), these findings suggest continuing serum ATA
antibody production throughout the course of the experi-
ment, without requirement of constant resupply from the
spleen, consistent with the cell transfer experiment. The
immediate drop in ATA titer was likely due to the loss of
preexisting AA4.1  CD23  B-1 cells as a minor compart-
ment in the spleen, which may have been generated by de-
velopment distinct from the primary BM pathway.
In ATA    Tg mice, AA4.1  B cells in the spleen
showed 60% BrdU labeling after a short-term pulse (Fig. 2
C). 10% of PerC ATA B cells were BrdU labeled, likely
representing cells migrated from the spleen or directly from
BM (Fig. 5 E, left). These rapidly labeled cells did not per-
sist in PerC, but rather showed a similar turnover rate as
the spleen BrdU  B cells (Figs. 5 E and 2 B). In contrast to
such results with ATA   Tg mice, analysis of PerC B cells
in ATA  Tg mice revealed a self-antigen–dependent in-
crease in CD5  ATA B cells (Fig. 1) and such cells did not
incorporate BrdU (Fig. 5 E, middle), consistent with the
idea of positive selection and similar to the CD5  B cells in
normal mice (Fig. 5 E, right), known to be long-lived and
predominantly noncycling (35, 37). These findings suggest
a shift in the balance between positive and negative selec-
tion in the PerC B cell population, where negative selec-
tion predominates in ATA   Tg mice, resulting in a lack
of significant ATA B cell accumulation. Serum antibody
production observed in our PerC B cell transfer from
ATA   Tg mice was likely contributed by the B-1 B cells
present as a minor population.
Natural Serum Autoantibody in Association with Peritoneal
B-1. Dissociation of serum autoantibody production
from conventional BM B cell development was addition-
ally substantiated by analysis of Thy-1 /  ATA    Tg
mice. As shown in Fig. 5 B, in Thy-1 /  ATA   Tg
mice, the lack of ATA in serum was compensated by
non-ATA IgM produced by B cells that rearranged en-
dogenous Ig loci (IgMb), reaching 70% of the normal IgM
level. This serum profile was in clear contrast with the
complete absence of B cells bearing endogenous BCRs in
most lymphoid organs populated by BM-derived B cells,
including the spleen, lymph nodes, mesenteric lymph
nodes, and the lymphoid follicles in the gut known as
Peyer’s patches, but with the notable exception of PerC
(Fig. 6 A). The IgMa  B cells in Thy-1    mice were all
ATA Id  B cells and consisted predominantly of AA4.1 
CD23  mature naive follicular B cells, with some naive
ATA B cells also detected in the PerC (Fig. 6 A). How-
ever, a large proportion of the PerC B cells expressed en-
dogenous IgMb together with CD5 expression (Fig. 6 B),
a phenotype typical of (self)-antigen–exposed B-1 B cells
in PerC (Fig. 6 B). In contrast, naive ATA B cells in PerC
were CD5  due to the absence of Thy-1. Thus, there was
no B-1 positive selection and a lack of serum antibody
contribution. These findings emphasize the significance of
a self-antigen–dependent mechanism for the production
of natural serum antibody in association with B-1 B cell
generation.
Discussion
We have demonstrated here that VH3609 /V 21C-
encoded ATA B cells are negatively selected in the major
pathway of BM B cell development. The majority of ATA
B cells in the spleen showed maturational arrest. They are
short-lived, replaced rapidly from the BM, and are unlikely
to be the major source of natural serum ATA. Instead, cells
already established outside of conventional lymphoid or-
gans, together with preexisting B-1 cells in the spleen (12,
20), appear to play a significant role in the self-antigen–
dependent production of serum ATA. These positively se-
lected B-1 cells could be revealed more readily in PerC of
ATA -only Tg mice, due to a lower proportion of nega-
tively selected cells, such that CD5  B cells constitute a sig-
nificant fraction of the PerC B cells, more similar to normal
mice. In contrast, in ATA   Tg mice, forced expression of
the ATA specificity by all BM immature B cells resulted in
predominant negative selection, even in the PerC popula-
tion, whereas the serum ATA level was intact, independent
from negative selection and likely contributed by the pres-
ence of infrequent B-1 B cells. Recent reports describing
normal or even elevated serum immunoglobulin levels inT
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mice lacking most peripheral B cells due to blocked BM
development resulting from absence of IL-7 (38) or condi-
tional deletion of Rag-2 (37) are consistent with this no-
tion. Taken together, BM-derived B cell development and
selection in conventional lymphoid organs seems unlikely
to produce the B-1 cells that participate in the daily pro-
duction and maintenance of natural serum autoantibody in
normal healthy individuals.
CD5 induction, commonly thought to mark B-1 cells,
nonetheless occurred for BM-derived ATA immature B
cells during negative selection as a result of self-antigen ex-
posure. Thus, CD5 induction can occur during B cell de-
velopment, but before cell fate is determined, either nega-
tively as shown here, or positively as found with positive
selection in T cell development (39). It should be empha-
sized, however, that these CD5-induced B cells from BM
are not equivalent to long-lived B-1 cells generated after
positive selection as our serum ATA data indicated, and
that the induction of CD5 is not a general consequence for
all self-antigen–exposed tolerant B cells. Despite the expec-
tation that negative selection will be frequent during BM B
cell development (3), CD5 induction is normally rare (19,
40) and typically absent from, or present at very low levels
on, tolerant B cells (28). Only B cells expressing the proto-
typic ATA    chain became CD5  in ATA   Tg mice.
Thus, CD5 induction from immature B cells appears to re-
quire specific types of antigen or a specific threshold of
BCR signaling. Previously, it was considered that the pau-
city of CD5 induction during BM B cell development
might be due to a relative decrease of B-1–associated speci-
ficities in the newly generated B cell repertoire by either
increasing diversity in  -heavy chain rearrangement (41,
Figure 6. Predominance of endogenous Ig-expressing B-1 cells in PerC of Thy-1 
ATA   Tg mice. (A) Predominance of mature naive ATA B cells in conventional lym-
phoid organs, except for PerC, without Thy-1. Analysis of 3369 Thy-1    mice.
CD23/AA4.1 profiles of IgMa  ATA Id  cells (boxed regions at the top) are shown on
the bottom. (B) CD5 expression predominantly on the endogenous    (Endo  ) B cells
in the PerC of a 3369 Thy-1    mouse.T
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42) or altered pre-BCR selection (21, 43). This study sug-
gests that even if generated, B cells with such specificities
will likely make little or no contribution to any mature B
cell pool in normal mice.
The finding of a positive impact of self-antigen on serum
autoantibody levels, first reported for the heavy-only
6C10-  Tg line and shown here with ATA-   Tg mice,
stands in sharp contrast to most other models of B cell au-
toreactivity where the presence of autoantigen has negative
effects (4–6, 31, 44, 45). One other previously reported ex-
ception is an RF Tg model where the presence of antigen
has little effect, either negative or positive, leading to the
description of this Tg BCR as “clonally indifferent” in nor-
mal mouse background (46, 47). This has been attributed
to the relatively low affinity of this BCR for antigen, as a
higher affinity RF model shows strong antigen-mediated
central tolerance in the presence of antigen (47, 48). The
ATA BCR does not appear to exhibit a particularly low af-
finity for antigen, as the presence of high levels of Tg-
encoded serum autoantibody is accompanied by arrested B
cell development and/or elimination of the specificity in
the spleen by receptor editing. This suggests that the ATA
specificity, representative of a B-1–associated natural au-
toantibody, is regulated in a manner very distinct from pre-
vious models of autoreactivity associated with pathogenesis.
We have previously characterized B cell development in
another Tg model expressing a prototypic CD5  B-1–asso-
ciated specificity to a phosphatidylcholine-associated cryp-
tic determinant on erythrocytes revealed by treatment with
the proteolytic enzyme bromelain (49, 50). Unlike the
ATA specificity, however, B cells in this BR1-VH11/V 9
model did not edit nor show obvious signs of anergy in the
spleen, but instead adopted a typical B-1 phenotype and
showed evidence of extended survival in culture (50). Al-
though a definitive explanation for this difference remains
to be determined, recent analysis of a VH11 knock-in
mouse (unpublished data) indicates that physiological ex-
pression of this heavy chain results in accumulation of a
fraction of VH11V 9 B cells in spleen showing the “arrested
development” phenotype, as described here with ATA
BCR animals. Quantitative differences in the level of BCR
between these lines might be responsible for such a differ-
ent outcome. In addition, differences in ATA versus phos-
phatidylcholine B cell development could arise from varia-
tions in the expression level of the antigens. These are
issues that we are currently investigating.
There has been emerging interest on the origin of natu-
ral serum autoantibody and its relevance to antibodies to
virus or commensal bacteria. The constitutive presence of
neutralizing antibody in serum is essential, protecting
against viral or bacterial replication to prevent potentially
lethal disease progression, playing a role as a part of innate
immunity (51–54). Natural autoantibodies are often reac-
tive to carbohydrate on self-antigens (16, 55), which might
be shared with determinants on bacterial, viral, or tumor
antigens. These observations have led to the hypothesis that
positive selection of the autoreactive B cell repertoire
might be an active process to provide protective immunity
for immunological surveillance. Previously, it was specu-
lated that these self-antigens might be unique, being ineffi-
cient in inducing tolerance (26, 56). However, our study
shows that these natural autoantigens can function as
tolerogens, similar to classical autoantigens. The transfer of
fetal B cell progenitors, but not adult BM B cell progeni-
tors, into the adult mouse environment resulted in B-1 cell
positive selection, i.e., accumulation of CD5  B cells (20).
This raises the additional possibility that differences of im-
mature B cell responsiveness that specifically allow B-1 cell
positive selection may also account for autoreactive B cell
production from such fetal precursors.
Serum ATA is already detectable in the fetus and new-
borns of ATA Tg mice (17, 57) before BM B cell develop-
ment is established, supporting the idea that B-1 cell posi-
tive selection occurs before birth. Some B-1 cells are
maintained throughout life by self-renewal (12) as a persist-
ing fetal/neonatal B-1 cell population, although it is likely
that some B-1 cells might be generated continuously from
precursors in the BM as a minor divergent pathway. The
intestinal lamina propria appears to serve as a major site for
B-1 cell differentiation into antibody-secreting cells and
class switching to IgA (13, 33) in normal mice. Interest-
ingly, there is a significant level of endogenous (non-ATA)
IgA secretion in ATA   Tg mice as found with other Ig
Tg B cell mouse models (33, 58), suggesting a strong ongo-
ing serum antibody production separate from the majority
of BM B cell development. Unique IgA production in the
gut lamina propria in mice deficient for the majority of B
and T cells has been reported (59, 60). These findings sug-
gest that there are B cell system(s) that actively provide
protective immunity independent from the majority of B
cell development in the adult. B-1 cell development may
represent such a system, uniquely allowing positive selec-
tion to self- and/or commensal antigens. This is an impor-
tant issue to address in future studies.
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